#1 - Moderna (NASDAQ:MRNA)
Moderna (NASDAQ:MRNA) may not be the first name you think of when it comes to ESG stocks. However, the company currently has a 72.6% Net Impact Ratio largely due to the impact it is having on reducing physical diseases due to its Covid-19 vaccine. While it’s difficult to say how much future vaccine revenue will be coming in the door. But, the fact that an mRNA vaccine is now in the market bodes well for other vaccines in the company’s pipeline.
MRNA stock is down 66% from its 52-week high. Some of that is due to the company’s last earnings report in November in which the company missed on both the top and bottom lines. And second, the stock is being sold off as part of the flight to risk-off assets.
Right now, Moderna stock is a hold based on the consensus opinion of analysts tracked by MarketBeat. However, the company recently received full FDA approval for its mRNA vaccine. And that is not yet being factored into the analyst ratings. Even without that approval being factored in, MRNA stock has a consensus price target of $245.21 which gives it a 49% upside.
About Moderna
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Read More - Current Price
- $39.39
- Consensus Rating
- Hold
- Ratings Breakdown
- 6 Buy Ratings, 12 Hold Ratings, 4 Sell Ratings.
- Consensus Price Target
- $79.50 (101.8% Upside)
